Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.65 |
| ▸ | TERT | O14746 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301232 | 1.00 | DTYMK (0.65) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL30632043 | 0.96 | DTYMK (0.66) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL16983788 | 0.96 | DTYMK (0.66) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL16979766 | 0.96 | DTYMK (0.66) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL14174120 | 0.96 | F2 (0.64) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29423008 | 0.96 | F2 (0.64) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL14184947 | 0.96 | F2 (0.64) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL32665846 | 0.96 | F2 (0.64) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29387073 | 0.96 | F2 (0.64) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29959672 | 0.96 | F2 (0.64) | DTYMKTERTF2RNASELP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026351-A1 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING TRAC AND USES THEREOF | Arbor Biotechnologies, Inc. (US) | 2024-01-25 | — | — | US | claimed |
| WO-2023075154-A1 | METHOD FOR INACTIVATING GENE OF PORCINE ENDOGENOUS RETROVIRUS AND COMPOSITION THEREOF | 주식회사 툴젠 | 2023-05-04 | — | — | WO | claimed |
| US-12630839-B2 | Compositions for the treatment of Fabry disease | SANGAMO THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4696310-A2 | METHODS AND COMPOSITIONS FOR MODULATION OF TAU PROTEINS | Sangamo Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3860618-B1 | COMPOSITIONS FOR TREATING TAUOPATHY | SANGAMO THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20260009038-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | UNIV ARIZONA STATE (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260009027-A1 | PRIME EDITING-MEDIATED READTHROUGH OF PREMATURE TERMINATION CODONS (PERT) | THE BROAD INSTITUTE, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4667565-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE | Sangamo Therapeutics, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12492411-B2 | Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4652272-A1 | PRIME EDITING-MEDIATED READTHROUGH OF PREMATURE TERMINATION CODONS (PERT) | The Broad Institute Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250313848-A1 | ENGINEERED GENETIC MODULATORS | SANGAMO THERAPEUTICS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| US-11401512-B2 | Engineered target specific nucleases | SANGAMO THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220175839-A1 | TARGETED DISRUPTION OF THE MHC CELL RECEPTOR | SANGAMO THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2022119367-A1 | TRANSGENIC ANIMAL HAVING MODIFIED MYOSTATIN GENE | ㈜라트바이오 | 2022-06-09 | — | — | WO | disclosed |
| CN-108738326-B | Novel CRISPR-associated transposase and use thereof | 孟山都技术公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-108024544-B | Delivery methods and compositions for nuclease-mediated genome engineering | 桑格摩生物治疗股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11285175-B2 | Targeted disruption of the MHC cell receptor | SANGAMO THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3964573-A1 | ENGINEERED TARGET SPECIFIC NUCLEASES | Sangamo Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3955916-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | Buck Institute for Research on Aging (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3946384-A1 | METHODS FOR THE TREATMENT OF BETA-THALASSEMIA | Sangamo Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009027-A1 | PRIME EDITING-MEDIATED READTHROUGH OF PREMATURE TERMINATION CODONS (PERT) | NSUN3, UPF1, TRMT1L | DTYMK 423/4885TERT 407/4885F2 3513/4885 |
| US-20260009038-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | ADAR, ADA, YARS1 | DTYMK 105/4885TERT 1125/4885F2 4857/4885 |
| US-11401512-B2 | Engineered target specific nucleases | ZFR, ZFX, HELZ | DTYMK 25/4885TERT 2547/4885F2 3683/4885 |
| US-12630839-B2 | Compositions for the treatment of Fabry disease | APOB, HBB, GLA | DTYMK 3677/4885TERT 2736/4885F2 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.